MA45656A - Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1 - Google Patents
Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1Info
- Publication number
- MA45656A MA45656A MA045656A MA45656A MA45656A MA 45656 A MA45656 A MA 45656A MA 045656 A MA045656 A MA 045656A MA 45656 A MA45656 A MA 45656A MA 45656 A MA45656 A MA 45656A
- Authority
- MA
- Morocco
- Prior art keywords
- vanin
- enzyme inhibitors
- new pyrimidine
- pyrimidine carboxamides
- carboxamides used
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662362098P | 2016-07-14 | 2016-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45656A true MA45656A (fr) | 2021-03-24 |
Family
ID=59351004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045656A MA45656A (fr) | 2016-07-14 | 2017-07-07 | Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10906888B2 (fr) |
EP (1) | EP3484876A1 (fr) |
JP (1) | JP2019524716A (fr) |
KR (1) | KR20190026902A (fr) |
CN (1) | CN109476645A (fr) |
AU (1) | AU2017296338A1 (fr) |
BR (1) | BR112019000589A2 (fr) |
CA (1) | CA3030381A1 (fr) |
IL (1) | IL263662A (fr) |
MA (1) | MA45656A (fr) |
MX (1) | MX2019000536A (fr) |
RU (1) | RU2019100559A (fr) |
SG (1) | SG11201811161YA (fr) |
WO (1) | WO2018011681A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
PL3638680T3 (pl) * | 2017-06-12 | 2022-12-19 | Boehringer Ingelheim International Gmbh | Związki heteroaromatyczne jako inhibitory waniny |
WO2019133445A1 (fr) * | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1 |
AU2019326933A1 (en) * | 2018-08-28 | 2021-01-28 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
AU2019335200A1 (en) * | 2018-09-04 | 2021-03-11 | Theravance Biopharma R&D Ip, Llc | 5 to 7 membered heterocyclic amides as JAK inhibitors |
US11078182B2 (en) * | 2018-12-03 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
CA3120037A1 (fr) * | 2018-12-03 | 2020-06-11 | Boehringer Ingelheim International Gmbh | Composes heteroaromatiques utilises en tant qu'inhibiteurs de vanine |
CA3120036A1 (fr) * | 2018-12-03 | 2020-06-11 | Boehringer Ingelheim International Gmbh | Composes heteroaromatiques utilises en tant qu'inhibiteurs de vanine |
CN111388452B (zh) * | 2020-04-30 | 2021-10-26 | 中国药科大学 | 脂肪组织靶向肽p3-壳聚糖寡聚乳酸-聚乙二醇递送系统及其在核酸药物递送上的应用 |
KR20230049673A (ko) * | 2020-09-25 | 2023-04-13 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 피리미딘 카르복스아미드 화합물 및 이의 용도 |
CN114644640B (zh) * | 2020-12-17 | 2024-05-14 | 上海美悦生物科技发展有限公司 | 一种嘧啶甲酰胺类化合物及其应用 |
CN114933594A (zh) * | 2022-07-20 | 2022-08-23 | 北京科翔中升医药科技有限公司 | 一种氟代三嗪类化合物、药物组合物及用途 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5508424A (en) | 1993-03-26 | 1996-04-16 | Ortho Pharmaceutical Corporation | 4-arylisoindole analgesics |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5811428A (en) | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GEP20033114B (en) | 1998-07-06 | 2003-11-25 | Bristol Myers Squibb Co | Biphenyl Sulfonamides as Dual Angiotensin Endothelin Receptor Antagonists, Method for Their Production and Pharmaceutical Compositions Containing the Same |
MXPA01010292A (es) | 1999-04-15 | 2002-10-23 | Squibb Bristol Myers Co | Inhibidores ciclicos de la proteina tirosina cinasa. |
IL145922A0 (en) | 1999-04-28 | 2002-07-25 | Aventis Pharma Gmbh | Di-aryl acid derivatives as ppar receptor ligands |
CA2374650A1 (fr) | 1999-05-24 | 2000-11-30 | Penglie Zhang | Inhibiteurs du facteur xa |
CA2383466C (fr) | 1999-09-16 | 2009-08-25 | Tanabe Seiyaku Co., Ltd. | Composes cycliques aromatiques azotes a six elements |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
NZ522217A (en) | 2000-04-28 | 2004-04-30 | Tanabe Seiyaku Co | Cyclic compounds |
US20020183316A1 (en) | 2000-10-27 | 2002-12-05 | Kevin Pan | Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders |
AU2002324716A1 (en) | 2001-08-17 | 2003-03-03 | Bristol-Myers Squibb Company Patent Department | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
IL163659A0 (en) | 2002-02-27 | 2005-12-18 | Pfizer Prod Inc | Acc inhibitors |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
AU2003228701A1 (en) | 2002-04-25 | 2003-11-10 | Bristol-Myers Squibb Company | Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases |
MXPA05011521A (es) | 2003-04-28 | 2006-01-23 | Astellas Pharma Inc | Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo. |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
AU2005210039B2 (en) | 2004-02-04 | 2010-09-02 | Neurosearch A/S | Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands |
JP4845873B2 (ja) | 2004-03-03 | 2011-12-28 | ケモセントリックス インコーポレーティッド | 二環式および架橋した窒素複素環 |
US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
US7423147B2 (en) | 2004-03-31 | 2008-09-09 | Janssen Pharmaceutical, N.V. | Pyridine compounds as histamine H3 modulators |
ATE437870T1 (de) | 2004-05-12 | 2009-08-15 | Pfizer Prod Inc | Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren |
ES2297727T3 (es) | 2004-06-09 | 2008-05-01 | F. Hoffmann-La Roche Ag | Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos. |
AU2005296124A1 (en) | 2004-10-13 | 2006-04-27 | Neurogen Corporation | Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor |
JP4765545B2 (ja) | 2004-10-27 | 2011-09-07 | アステラス製薬株式会社 | ベンゾアゼピン誘導体を有効成分とする医薬組成物 |
PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
WO2007093520A1 (fr) | 2006-02-15 | 2007-08-23 | F. Hoffmann-La Roche Ag | Composes antiviraux heterocycliques |
WO2007122482A1 (fr) | 2006-04-20 | 2007-11-01 | Pfizer Products Inc. | Composés phényle amido-hétérocycliques fusionnés pour la prévention et le traitement de maladies à médiation par glucokinase |
JP2010511035A (ja) | 2006-11-29 | 2010-04-08 | ファイザー・プロダクツ・インク | スピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
KR100909953B1 (ko) | 2007-06-15 | 2009-07-31 | 한국화학연구원 | 항진균 활성을 갖는 트라이아졸 유도체, 이의 제조방법 및이를 함유하는 약학 조성물 |
WO2008157552A2 (fr) | 2007-06-18 | 2008-12-24 | Mayo Foundation For Medical Education And Research | Inhibiteur d'acétylcholinestérase d'invertébrés |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
WO2009016498A1 (fr) | 2007-08-02 | 2009-02-05 | Pfizer Inc. | Dérivés de pyrimidine et de pyridine et leur utilisation pharmaceutique et leurs compositions |
ES2545231T3 (es) | 2008-05-28 | 2015-09-09 | Pfizer Inc. | Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa |
CA2724603A1 (fr) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Inhibiteurs de la pyrazolospirocetone acetyl-coa carboxylase |
JP2011529483A (ja) | 2008-07-29 | 2011-12-08 | ファイザー・インク | フッ素化ヘテロアリール |
UY32055A (es) | 2008-08-19 | 2010-03-26 | Astrazeneca Ab | Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones. |
WO2010023594A1 (fr) | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dérivés de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol |
WO2010086820A1 (fr) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle |
WO2010103438A1 (fr) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Indazole amides substitués |
PL2406253T3 (pl) | 2009-03-11 | 2013-10-31 | Pfizer | Pochodne benzofuranylu jako inhibitory glukokinazy |
CA2754523A1 (fr) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3,3.1]nonanes |
EP2415765A4 (fr) | 2009-03-30 | 2012-08-15 | Astellas Pharma Inc | Composé pyrimidine |
JP2012526097A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Gpr119調節因子 |
JP2012526096A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Gpr119調節因子 |
US9040538B2 (en) | 2009-05-21 | 2015-05-26 | Universite Laval | Pyrimidines as novel therapeutic agents |
SG175995A1 (en) | 2009-06-05 | 2011-12-29 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
WO2011005611A1 (fr) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de la neuromédine u et leurs utilisations |
WO2011133920A1 (fr) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
DK2565182T3 (en) | 2010-04-27 | 2017-12-04 | Mitsubishi Tanabe Pharma Corp | New amide derivative and its use as a drug |
NZ705135A (en) | 2010-05-26 | 2017-10-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
ES2823350T3 (es) | 2010-07-29 | 2021-05-06 | Rigel Pharmaceuticals Inc | Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos |
US9193705B2 (en) | 2010-09-01 | 2015-11-24 | President And Fellows Of Harvard College | Small molecule inhibitors of ebola and lassa fever viruses and methods of use |
WO2012068589A2 (fr) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
EP2651404B1 (fr) | 2010-12-14 | 2015-10-14 | Electrophoretics Limited | Inhibiteurs de caséine kinase 1 delta (ck1delta) |
RU2014115476A (ru) | 2011-09-20 | 2015-10-27 | Целльзом Лимитед | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ |
WO2013067710A1 (fr) * | 2011-11-11 | 2013-05-16 | Abbott Laboratories | Inhibiteurs de la nampt |
EP2834269A4 (fr) | 2012-04-02 | 2015-12-30 | Cytokinetics Inc | Procédés d'amélioration de la fonction de diaphragme |
AU2013245917A1 (en) | 2012-04-11 | 2014-10-23 | Cytokinetics, Inc. | Improving resistance to skeletal muscle fatigue |
AU2013324696B2 (en) * | 2012-09-25 | 2017-09-14 | Merck Patent Gmbh | Alpha hydroxy amides |
EP2925321A4 (fr) | 2012-11-27 | 2016-04-27 | Merck Sharp & Dohme | Composés de 2-pyridylamino-4-nitrile-pipéridinyl, antagonistes des récepteurs de l'orexine |
WO2014181287A1 (fr) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Composés hétérocyclyliques et leurs utilisations |
US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
EP3303303A1 (fr) * | 2015-05-29 | 2018-04-11 | Pfizer Inc | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1 |
-
2017
- 2017-07-07 US US16/316,688 patent/US10906888B2/en active Active
- 2017-07-07 JP JP2019500621A patent/JP2019524716A/ja active Pending
- 2017-07-07 RU RU2019100559A patent/RU2019100559A/ru not_active Application Discontinuation
- 2017-07-07 EP EP17740116.3A patent/EP3484876A1/fr not_active Withdrawn
- 2017-07-07 MX MX2019000536A patent/MX2019000536A/es unknown
- 2017-07-07 CA CA3030381A patent/CA3030381A1/fr not_active Abandoned
- 2017-07-07 WO PCT/IB2017/054104 patent/WO2018011681A1/fr unknown
- 2017-07-07 AU AU2017296338A patent/AU2017296338A1/en not_active Abandoned
- 2017-07-07 BR BR112019000589-7A patent/BR112019000589A2/pt not_active Application Discontinuation
- 2017-07-07 SG SG11201811161YA patent/SG11201811161YA/en unknown
- 2017-07-07 KR KR1020197004221A patent/KR20190026902A/ko not_active Application Discontinuation
- 2017-07-07 MA MA045656A patent/MA45656A/fr unknown
- 2017-07-07 CN CN201780043514.7A patent/CN109476645A/zh not_active Withdrawn
-
2018
- 2018-12-12 IL IL263662A patent/IL263662A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN109476645A (zh) | 2019-03-15 |
KR20190026902A (ko) | 2019-03-13 |
IL263662A (en) | 2019-01-31 |
US20190315715A1 (en) | 2019-10-17 |
BR112019000589A2 (pt) | 2019-04-24 |
US10906888B2 (en) | 2021-02-02 |
WO2018011681A1 (fr) | 2018-01-18 |
SG11201811161YA (en) | 2019-01-30 |
EP3484876A1 (fr) | 2019-05-22 |
JP2019524716A (ja) | 2019-09-05 |
MX2019000536A (es) | 2019-04-01 |
AU2017296338A1 (en) | 2019-01-03 |
RU2019100559A3 (fr) | 2020-07-14 |
CA3030381A1 (fr) | 2018-01-18 |
RU2019100559A (ru) | 2020-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45656A (fr) | Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1 | |
HK1256857A1 (zh) | 多氟化合物作為布魯頓酪氨酸激酶抑制劑 | |
MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
CL2018002892A1 (es) | Composiciones de conjugado de ácido nucleico dirigido. | |
DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
DK3433368T3 (da) | Transreplikerende rna | |
DK3341482T3 (da) | Kunstige nukleinsyremolekyler | |
DK3502253T3 (da) | Hidtil ukendte crispr-enzymer og -systemer | |
MA51229A (fr) | Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr | |
MA42597A (fr) | 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA41014A (fr) | Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique | |
MA41252A (fr) | Formes solides d'un inhibiteur d'ask 1 | |
MA45646A (fr) | Derives de benzimidazole comme des modulateurs de ror-gamma | |
FR3015187B1 (fr) | Utilisation d'une composition renfermant du 1,3-propanediol comme e-liquide | |
MA43761A (fr) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj | |
WO2015112896A3 (fr) | Méthodes et compositions pour des séquences guidant le ciblage de cas9 | |
FR3020060B1 (fr) | Preparation d'imides contenant un groupement fluorosulfonyle | |
MA41977A (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
MA41677A (fr) | Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8 | |
EP3174539A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
EP3141546A4 (fr) | Inhibiteur de la tyrosine kinase de bruton | |
DK3116475T3 (da) | Dopa-decarboxylasehæmmersammensætninger | |
BR112016020181A2 (pt) | Composições de ácido lipoico éster colina e métodos de uso. | |
MA42510A (fr) | Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton |